Cancer Immunotherapy Market Garner Above USD 309.70 Billion In 2030, Globally, Driven By Rapid Development Of Healthcare Industry

Pune, Maharashtra, India, September 12 2022 (Wiredrelease) Prudour Pvt. Ltd –:[250+ market report pages] The global cancer immunotherapy market size was valued at $85.8 billion in 2020, and is projected to reach $309.70 billion by 2030, registering a CAGR of 14.5% from 2021 to 2030.

Cancer immunotherapy is a type of cancer treatment that uses the patient’s own immune system to fight the cancer. The immune system is a complex system of cells and proteins that helps the body fight off infections and other diseases. Cancer cells are abnormal cells that grow out of control. The immune system recognizes these abnormal cells and tries to destroy them. However, sometimes the cancer cells grow faster than the immune system can kill them. Cancer immunotherapy helps the immune system work better against cancer cells. Growing adoption of advanced cancer therapeutic options coupled with rising cancer incidence has been one of the primary growth stimulants for the market. Healthcare providers are focusing on improving cancer therapeutic facilities and a reduction in the recurrence rate of tumor post chemotherapy.

GLOBOCAN 2018 shows that cancer incidence has increased from 14.1million to 15.2 million between 2012 and 2015 to 17.0million by 2018, an increase of around 12%. In addition, cancer mortality has seen a rise, from 8.2million deaths in 2012 to a 9.4 million deaths in 2018. According to the American Cancer Society, lung cancer ranks as one of the world’s most deadly forms of cancer.

There are different types of cancer immunotherapy.

Cancer immunotherapy is a type of cancer treatment that uses the body’s own immune system to fight the cancer. The immune system is a complex system of cells and organs that work together to protect the body from infection and disease. 

Cancer immunotherapy treatments can be divided into two main types: active and passive. 

Active immunotherapy treatments stimulate the body’s own immune system to recognize and attack cancer cells. Passive immunotherapy treatments use man-made versions of antibodies or immune cells to directly attack cancer cells. There are many factors, such as increase in healthcare expenditure, rise in incidence of cancer, surge in access to medical insurance, and surge in technological advancements in cancer treatment therapies expected to propel the growth of the global cancer immunotherapy market.

Download PDF Sample with Recent all Updates and Trending Key Players with TOC @ https://market.us/report/cancer-immunotherapy-market/request-sample/

Recent Developments

* Amgen’s LUMAKRAS was approved by the US FDA for use in treating KRAS G12C patients. This involves metastatic or mutated non-small cell lung carcinoma (NSCLC) and has been approved by Amgen in May 2021. LUMAKRAS is a targeted treatment for NSCLC.

* Astellas Pharma announced that the European Commission approved the XTANDI therapy (enzalutamide) in May 2021. XTANDI, the only approved oral treatment available for prostate cancer, is approved for all three types: non-metastatic, metastatic hormone sensitve, and resistant to metastatic castration.

Scope of the Report:

Type

Monoclonal Antibodies
Immunomodulators
Oncolytic Viral Therapies and Cancer Vaccines

Application

Lung Cancer
Breast Cancer
Colorectal Cancer
Melanoma
Prostate Cancer
Head and Neck Cancer
Ovarian Cancer
Pancreatic Cancer

Request For Covid-19 Impact Analysis On Cancer Immunotherapy Market: https://market.us/request-covid-19/?report_id=67380

Key Market Players included in the report:

Amgen Inc.
AstraZeneca
F. Hoffmann La Roche Ltd.
Bayer AG
Bristol-Myers Squibb Company
Eli Lilly and Company
Merck and Co. Inc.
Novartis AG
Pfizer Inc.

Regional Insights

North America Cancer Immunotherapy Market Revenue and Opportunities Forecast 2022-2031

U.S.

Canada

Europe Cancer Immunotherapy Market Revenue and Update Forecast 2022-2031

UK

Germany

France

Rest of Europe 

Asia Pacific Cancer Immunotherapy Market Revenue and Forecast Analysis 2022-2031

China 

Japan

India 

Rest of Asia Pacific 

Latin America Cancer Immunotherapy Market Revenue and Global Forecast 2022-2031

Mexico 

Brazil 

Rest of Latin America 

The Middle East and Africa Cancer Immunotherapy Market Revenue and Forecast Overview 2022-2031

GCC Countries 

South Africa 

Rest of the Middle East and Africa 

To turn massive challenges into meaningful change, Make an Inquiry of the report@ https://market.us/report/cancer-immunotherapy-market/#inquiry  

Frequently Asked Questions About This Report

How big is the immunotherapy market?

What percentage of cancer patients receive immunotherapy?

What is the most successful cancer immunotherapy approaches?

What are the key companies in cancer immunotherapy market?

What are cancer immunotherapy market opportunities?

What is the cancer immunotherapy market growth rate?

How big is the cancer immunotherapy market size?

What is the largest segment of cancer immunotherapy market?

Media Contact

Company Name: Market.us (Powered By Prudour Pvt. Ltd.)

Global Business Development Teams – Market.us

Email: inquiry@market.us

Phone: +1 718 618 4351

Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Top Selling Reports:

Global Cancer Treatment Drugs Market Size, Trends, Scope and Growth Analysis to 2031

Global Pet Cancer Therapeutics Market Key Vendors, Future Scenario Forecast to 2031

Global Oncolytic Virus Therapies Market Size | Assessment, Key Factors and Challenges by 2031

Global Cell Therapy Monitoring Kits Market Trend | Future Prediction Report 2022-2031

 

This content has been published by Prudour Pvt. Ltd company. The WiredRelease News Department was not involved in the creation of this content. For press release service enquiry, please reach us at contact@wiredrelease.com.